Kinoxis Therapeutics

🇦🇺 This Week in Australian Startups #179, 26th September 2026

Weekly roundup recording a dozen raises and acquisitions, Firmus's scheduled float, a new $50m venture fund, a founder share sale, grant winners, an accelerator intake, and an AI agent's government breach.

Also Dynamic Business·DealStreetAsia·This Week in Australian Startups·Dealroom·ABC News Technology

Kinoxis Therapeutics closes $6.75 million financing round

Melbourne biotech Kinoxis completed a $6.75 million round with new backer MainSequence and won a $2.5 million government-funded CUREator+ grant for dementia and pain drug development; MainSequence's Elaine Stead joins the board.

Also Startup Daily·Startup Daily·Dealroom·This Week in Australian Startups·Dynamic Business

7 startups share $15.6 million in the latest round of government-backed dementia research grants

Seven Australian health startups receive equity-free grants totalling $15.6 million in the second CUREator+ round for dementia research, backed by the Medical Research Future Fund, spanning gene editing, medicines and diagnostic tools.

Also This Week in Australian Startups

Dementia biotech Kinoxis raises $6.75 million with a $2.5m grant as cherry on top

Melbourne dementia drug developer Kinoxis secured $6.75 million equity led by Main Sequence plus a $2.5 million Medical Research Future Fund grant via CUREator+, funding trials of its agitation and pain drug candidates.

Uniseed adds another $25m from UniSuper to commercialise academic research

UniSuper adds a further $25 million to its backing of Uniseed, reaching $100 million in total support for the university research commercialisation fund; past cheques to quantum and biotech startups are recapped.

CUREator+ Deploys $18.5 million in its First Funding Round

Eight Australian health startups received equity-free grants totaling 18.5 million dollars from the CUREator+ program, supported by government funding and delivered with partners Brandon BioCatalyst and ANDHealth.

Five ANZ startups that raised $38.5 million this week

Weekly roundup detailing five raises across Australian and New Zealand startups — Hapana, Kinoxis Therapeutics, Appetise, Bike Matrix and Aglow — worth a combined $38.5 million, naming lead investors and planned expansion for each.

Also SmartCompany·Startup Daily

Kinoxis secures $14.5m in funding and announces expansion of clinical programs to target agitation and aggression in dementia patients

Australian biotech Kinoxis Therapeutics raised $14.5 million in Series B backing from Uniseed, UniSuper and others to fund Phase 2 trials of KNX100 for dementia-related agitation, including a new Australian study.

Also SmartCompany·Startup Daily·Startup Daily

The Art of the Startup – Stoic

Interview with Stoic Venture Capital's Guy Hedley, Craig Swanger and Geoff Waring on backing university science startups, their Uniseed partnership, a planned 2024 All Stars Fund II, and new analyst Safaa Nasrallah.

Pioneering VC fund Uniseed doubles its backers as five universities, including Monash, UTS and Macquarie, chip in

Uniseed adds Monash and a four-university NSW collaboration, lifting its third fund by $6.75 million to $56.75 million; the article recalls past portfolio sales to Novartis, Shire and Schneider Electric.

Kinoxis snares $266 million for psychiatric drug

University of Sydney spinout Kinoxis Therapeutics signs a licensing and partnership deal with Boehringer Ingelheim to develop psychiatric treatments, with payments and R&D support worth up to $266 million.